These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38795205)

  • 1. Immune checkpoint inhibitor associated epidermal necrosis, beyond SJS and TEN: a review of 98 cases.
    Bray ER; Lin RR; Li JN; Elgart GW; Elman SA; Maderal AD
    Arch Dermatol Res; 2024 May; 316(6):233. PubMed ID: 38795205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitor-induced epidermal necrolysis: A narrative review evaluating demographics, clinical features, and culprit medications.
    Satoh TK; Neulinger MM; Stadler PC; Aoki R; French LE
    J Dermatol; 2024 Jan; 51(1):3-11. PubMed ID: 38031902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review.
    Maloney NJ; Ravi V; Cheng K; Bach DQ; Worswick S
    Int J Dermatol; 2020 Jun; 59(6):e183-e188. PubMed ID: 32052409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
    Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
    J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature.
    Ziemer M; Kardaun SH; Liss Y; Mockenhaupt M
    Br J Dermatol; 2012 Mar; 166(3):575-600. PubMed ID: 22014091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome.
    Jacobsen A; Olabi B; Langley A; Beecker J; Mutter E; Shelley A; Worley B; Ramsay T; Saavedra A; Parker R; Stewart F; Pardo Pardo J
    Cochrane Database Syst Rev; 2022 Mar; 3(3):CD013130. PubMed ID: 35274741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxic epidermal necrolysis with systemic lupus erythematosus: case report and review of the literature.
    Fan WY; Zhai QR; Ma QB; Ge HX
    Ann Palliat Med; 2022 Jun; 11(6):2144-2151. PubMed ID: 34412491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of histologic features of toxic epidermal necrolysis.
    Valeyrie-Allanore L; Bastuji-Garin S; Guégan S; Ortonne N; Bagot M; Roujeau JC; Revuz JE; Wechsler J; Wolkenstein P
    J Am Acad Dermatol; 2013 Feb; 68(2):e29-35. PubMed ID: 22088428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible involvement of CD14+ CD16+ monocyte lineage cells in the epidermal damage of Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Tohyama M; Watanabe H; Murakami S; Shirakata Y; Sayama K; Iijima M; Hashimoto K
    Br J Dermatol; 2012 Feb; 166(2):322-30. PubMed ID: 21936856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum and blister-fluid elevation and decreased epidermal content of high-mobility group box 1 protein in drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Carr DF; Wang CW; Bellón T; Ressel L; Nwikue G; Shrivastava V; Bergfeld W; Jorgensen AL; Chung WH; Pirmohamed M
    Br J Dermatol; 2019 Jul; 181(1):166-174. PubMed ID: 30613954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case Series of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis With Nivolumab and Nivolumab/ Ipilimumab Combination Therapy in Metastatic Melanoma.
    Lee O; Masood M; Nutan F
    J Drugs Dermatol; 2022 May; 21(5):529-530. PubMed ID: 35533039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: A case/non-case analysis using the Food and Drug Administration Adverse Event Reporting System.
    Godfrey H; Jedlowski P; Thiede R
    Australas J Dermatol; 2024 May; 65(3):243-253. PubMed ID: 38572842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients--Treatment and outcome.
    Yamane Y; Matsukura S; Watanabe Y; Yamaguchi Y; Nakamura K; Kambara T; Ikezawa Z; Aihara M
    Allergol Int; 2016 Jan; 65(1):74-81. PubMed ID: 26666483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis: frozen-section diagnosis.
    Hosaka H; Ohtoshi S; Nakada T; Iijima M
    J Dermatol; 2010 May; 37(5):407-12. PubMed ID: 20536645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mechanisms of Severe Cutaneous Adverse Reactions and a New Treatment Strategy].
    Saito Y; Nakamura R
    Yakugaku Zasshi; 2019; 139(12):1557-1562. PubMed ID: 31787645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A decade of burn unit experience with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: Clinical pathological diagnosis and risk factor awareness.
    Lim VM; Do A; Berger TG; Nguyen AH; DeWeese J; Malone JD; Jordan K; Hom F; Tuffanelli L; Fillari P; Siu S; Grossman R
    Burns; 2016 Jun; 42(4):836-43. PubMed ID: 26847613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxic epidermal necrolysis occurring with immune checkpoint inhibitors.
    Gopee NH; Gourley AM; Oliphant TJ; Hampton PJ
    Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical resemblance of widespread bullous fixed drug eruption to Stevens-Johnson syndrome or toxic epidermal necrolysis: report of two cases.
    Lin TK; Hsu MM; Lee JY
    J Formos Med Assoc; 2002 Aug; 101(8):572-6. PubMed ID: 12440088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in vietnamese spontaneous adverse drug reaction database: A subgroup approach to disproportionality analysis.
    Nguyen KD; Tran TN; Nguyen MT; Nguyen HA; Nguyen HA; Vu DH; Nguyen VD; Bagheri H
    J Clin Pharm Ther; 2019 Feb; 44(1):69-77. PubMed ID: 30129156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TNF-α induced extracellular release of keratinocyte high-mobility group box 1 in Stevens-Johnson syndrome/toxic epidermal necrolysis: Biomarker and putative mechanism of pathogenesis.
    Nwikue G; Olsson-Brown A; Aboheimed N; Yip V; Jolly C; Luchian A; Ressel L; Sharma A; Bergfeld W; Ahmed S; Dickinson A; Pirmohamed M; Carr DF
    J Dermatol; 2023 Sep; 50(9):1129-1139. PubMed ID: 37269158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.